New hope for tough ovarian cancer: CBX-12 trial launches
Disease control
Recruiting now
This study tests a new drug, CBX-12, in 40 women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if CBX-12 can shrink tumors and how safe it is at two different dose levels given every three weeks. Participants must have a specif…
Phase: PHASE2 • Sponsor: Cybrexa Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC